Aims: Diabetes-related complications have declined during the past two decades. We aimed to examine whether mortality in people with diabetes improved over time in the 1999 to 2010 National Health and Nutrition Examination Survey (NHANES).
cardiovascular events in patients with diabetes, 7 intensive interventions with multiple drug combinations and behaviour modification have proven beneficial effects on cardiovascular mortality. 8, 9 Patients with diabetes have reportedly become more successful in controlling their risk factors and have improved adherence to preventive practices. 10 Moreover, rates of diabetes-related complications have declined in the past 2 decades. 10, 11 Although mortality rates in patients with diabetes remain higher compared to those without diabetes, reductions in all-cause mortality in individuals with diabetes have occurred over time throughout the world. [12] [13] [14] [15] [16] Therefore, we aimed to examine whether there were improved outcomes over time 
| MATERIALS AND METHODS

| Data source and study population
This was a prospective cohort study using data from the US National 
| Definition of diabetes
We defined diabetes using 1 of the following 5 criteria: previous diagnosis of diabetes, intake of anti-diabetic medications or insulin, glycated haemoglobin level of ≥6.5%, fasting glucose level of ≥126 mg/dL, or a 2-h glucose level of ≥200 mg/dL after an oral glucose tolerance test. 17 A total of 5462 (44%) study participants without intake of anti-diabetic medications or insulin were checked for 2-h glucose levels. Participants who did not satisfy any of these 5 criteria were defined as without diabetes.
| Outcome measurements
Main outcome measurements in this study were total, cardiovascular, cardiac and cancer mortalities. Additionally, these mortality risks in the last decade were compared between participants with and without diabetes. We also investigated whether the causes of death in participants with or without diabetes changed.
We used publicly released mortality follow-up data, provided in Revision for deaths occurring in or after 1999. The specific codes used were as follows: I00-I09, I11, I13 and I20-I51 for causes of death from diseases of the heart (cardiac death); C00-C97 for causes of death from malignant neoplasms (cancer death); J40-J47 for causes of death from chronic lower respiratory tract diseases; V01-X59 and Y85-Y86 for causes of death from accidents; and I60-I69 for causes of death from cerebrovascular diseases. All other causes of death were residual. Cardiovascular death was defined as death resulting from cardiac and cerebrovascular diseases.
| Other measurements
We extracted data on potential confounders, including age, sex, race for African Americans. 20 Serum creatinine, urine albumin and urine creatinine levels were measured during mobile centre examination.
Ischaemic heart disease was defined as myocardial infarction or angina pectoris. Ischaemic heart disease and stroke were selfreported during home interview. analysis in participants with diabetes, we excluded those with missing information on education level (n = 5), smoking status (n = 4), BMI (n = 69), dyslipidaemia (n = 167) and hypertension (n = 5). We conducted additional analysis using the multivariable model, including history of ischaemic heart disease, stroke and cancer, and comorbidity of chronic kidney disease. We also performed Cox propor- To exclude the potential effect of a large increase in detection or diagnostic practices, we conducted sensitivity analyses limited to participants with ≥1 year duration of diabetes.
| Statistical analysis
All statistical analyses were conducted using STATA software were also calculated, using census 2000 population data, as the recommended standard population for the continuous NHANES dataset. 22 P values <.05 were considered statistically significant. Given the lack of statistical power inherent in the interaction tests, we used a P value cut-off of <.2 for such tests.
23,24
3 | RESULTS
| Baseline characteristics of US participants with and without diabetes
The characteristics of participants aged ≥20 years are presented in Among participants with diabetes, HbA1c levels were significantly lower and the proportion of individuals who used insulin was b Body mass index was calculated as weight in kg divided by the square of height in meters.
c Obesity was defined as body mass index ≥30 kg/m 2 .
d Dyslipidaemia was defined as previous diagnosis of hyperlipidaemia, intake of lipid lowering medications, low-density lipoprotein cholesterol levels of ≥160 mg/dL, high-density lipoprotein cholesterol levels of <40 mg/dL, or triglyceride levels of ≥200 mg/dL.
e Hypertension was defined as either a previous diagnosis of hypertension or documentation that the participant was taking anti-hypertensive medications.
f Chronic kidney disease was defined as impaired glomerular filtration rate of <60 mL/min/1.73 m 2 . 
| Mortality in participants with and without diabetes in the 1999 to 2010 group
Unadjusted Kaplan-Meier survival curves and event rates for total, cardiovascular, cardiac and cancer mortalities of all participants in the 1999 to 2010 group are shown in Figure S1 and Table S1 , respectively. When all datasets from the 1999 to 2010 NHANES were used, mean follow-up periods (AESD) were 6.6 AE 2.9 years in participants without diabetes and 5. Age-adjusted and multivariable-adjusted HRs for total, cardiovascular and cardiac deaths were also significantly higher in participants with diabetes than in those without diabetes, although the results for cancer death were not significantly different between participants with and without diabetes. Causes of death in all participants are presented in Figure S2 . The most common cause of death was heart dis- Table 2 .
Unlike those for participants in the 1999 to 2004 group, the cumulative event rates for total, cardiovascular and cardiac death did not significantly differ between participants with and without diabetes in the 2005 to 2010 group. These results did not change even when we used a narrower age categorization that spanned 5 years (Table S2) or limited participants to those who completed a 2-year follow-up (Table S3) . Additional adjustment, including history of ischaemic heart disease, stroke and cancer, and co-morbidity of chronic kidney dis- Abbreviations: CI, confidence interval; HR, hazard ratio.
a Data are presented as number, number (%), or hazard ratio (95% confidence interval).
b Multivariable adjustment was made for age (20-39, 40-59, 60-79, and ≥80 y), sex, race and ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and others), educational level (less than high school, high school graduation or General Education Development certificate, more than high school), current smoking status, body mass index, dyslipidaemia and hypertension.
significantly between participants with and without diabetes, for cardiac death, it was significantly higher in participants with diabetes than in those without diabetes (42.8% vs 11.7%, P < .001). (Table 3) . These results did not change using a narrower age categorization that spanned 5 years (Table S4) (Tables S5 and S6 ).
We Previously, the risk of myocardial infarction was similarly high in both diabetic populations without previous myocardial infarction and non-diabetic populations with previous myocardial infarction. 25 However, the number of deaths resulting from coronary heart disease between 1980 and 2000 in the USA markedly decreased because of advances in medical technology and pharmacologic treatment, along with substantial public health efforts to reduce cardiovascular risk factors. 26 Moreover, in the past decade, patients with diabetes have experienced a disproportionate reduction in in-hospital mortality over time and a complete reversal in risk of mortality relative to patients without diabetes. 27 In this study, mortality in the population with diabetes also decreased, particularly for cardiovascular and cardiac deaths. Increase in the prevalence of diabetes since 1999 might explain the increase in the proportion of patients with mild diabetes.
However, the sensitivity analysis, which was limited to patients with In conclusion, this study showed improved outcomes for total, cardiovascular and cardiac deaths in those with diabetes over time in the 1999 to 2010 US NHANES. Continuous nationwide evaluation of diabetes care and long-term follow-up studies are needed.
